Clinical-stage nuclear medicine company Radiopharm Theranostics (ASX:RAD) has announced the publication of positive results of a retrospective study of the biokinetics of 68Ga-RAD 301 in pancreatic cancer patients. …
Latest Video
New Stories
-
Radiopharm says targeted therapy demonstrates potential for pancreatic cancer patients
November 18, 2024 - -
CLINUVEL announces plan to prioritises three strategic programs
November 18, 2024 - - Latest News -
The records and decisions in one year show that everything happens for a reason
November 18, 2024 - - Latest News -
Industry nerves after Trump appoints RFK Jr to lead US Health and Human Services
November 18, 2024 - - Latest News -
Australian company's candidate reduces aggregation of key ALS disease target
November 17, 2024 - - Australian Biotech -
A response based on short-term considerations only undermines long-term objectives
November 15, 2024 - - Latest News -
Amplia enters into preclinical collaboration with Korean drug screening company
November 14, 2024 - - Australian Biotech